Who makes API 31510 1.5% Topical Cream?

API 31510 1.5% Topical Cream is developed by BPGbio.

What development phase is API 31510 1.5% Topical Cream in?

API 31510 1.5% Topical Cream is in Phase 1.

Last reviewed 2026-04-23 · How we verify

API 31510 1.5% Topical Cream

BPGbio · Phase 1 active Small molecule

At a glance

Generic name	API 31510 1.5% Topical Cream
Sponsor	BPGbio
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma (PHASE1, PHASE2)
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

API 31510 1.5% Topical Cream CI brief — competitive landscape report
API 31510 1.5% Topical Cream updates RSS · CI watch RSS
BPGbio portfolio CI